News from northwest biotherapeutics A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jun 04, 2019, 10:24 ET Highlights Of NW Bio's Program Update In The Industry Expert Theater Presentation At ASCO

Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers,...


May 30, 2019, 11:03 ET NW Bio To Present Updates On DCVax® Clinical Programs In Industry Theater Presentation At ASCO

Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers,...


May 28, 2019, 10:21 ET NW Bio Announces Settlement with Cognate BioServices Resolving Past Matters and Providing for Restart of DCVax®-Direct Production

Northwest Biotherapeutics (NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today...


Feb 26, 2019, 09:48 ET NW Bio Hires David Innes As Vice President, Investor Relations

Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers,...


Feb 08, 2019, 08:25 ET NW Bio Releases Voting Results From Annual Shareholders' Meeting

Northwest Biotherapeutics (OTCQB: NWBO) — ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor...


Jan 25, 2019, 08:59 ET Presentation By NWBio CEO At The Phacilitate Leaders World 2019 Conference

Northwest Biotherapeutics (OTCQB: NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor...


Dec 14, 2018, 08:59 ET NW Bio Announces That UK Property Transaction Has Closed, Including Funding of Approximately $47.3 Million Gross Proceeds

Northwest Biotherapeutics (OTCQB: NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor...


Dec 11, 2018, 08:32 ET NW Bio Announces Non-Dilutive Funding of Approximately $47.3 Million Through UK Property Transaction

Northwest Biotherapeutics (OTCQB: NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor...


Nov 19, 2018, 10:04 ET Updated Interim Data from Phase 3 Trial of DCVax®-L for Glioblastoma Presented at Society for Neuro-Oncology Conference

Northwest Biotherapeutics (OTCQB: NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor...


Nov 13, 2018, 08:30 ET NW Bio Announces $5 Million Bridge Funding

Northwest Biotherapeutics (OTCQB: NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor...


Aug 28, 2018, 14:08 ET NW Bio Announces Upcoming Presentation By Dr. Marnix Bosch At Immuno-Oncology Summit

Northwest Biotherapeutics (OTCQB: NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor...


Jun 01, 2018, 10:46 ET NW Bio discute des données intermédiaires de l'essai de phase 3 lors d'une session dans la salle de l'industrie pendant l'ASCO

Northwest Biotherapeutics (OTCQB : NWBO) (NW Bio), une société biotechnologique qui développe des immunothérapies personnalisées DCVax® destinées aux ...


Jun 01, 2018, 07:22 ET NW Bio wird die Zwischenergebnisse seiner Phase-3-Studie auf der Sitzung im Industry Theater während der ASCO besprechen

Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), ein Biotechnologieunternehmen, das unter der Bezeichnung DCVax® personalisierte Immuntherapien für...


Jun 01, 2018, 07:15 ET NW Bio trata datos de ensayo de fase 3 provisional en su sesión en el salón del sector de la ASCO

Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), empresa de biotecnología que desarrolla la inmunoterapias personalizadas DCVax® para cánceres con...


May 31, 2018, 11:15 ET NW Bio To Discuss Interim Phase 3 Trial Data In Industry Theater Session During ASCO

Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers,...


May 31, 2018, 07:32 ET NW Bio discute dados provisórios da fase 3 na sessão de especialistas do setor durante a ASCO

A Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), uma empresa de biotecnologia, que desenvolve terapias imunológicas personalizadas para DCVax®...


May 31, 2018, 06:21 ET Společnost NW Bio prodiskutuje během konference ASCO prozatímní zkouškovou fázi 3 na semináři asociace Industry Theater

Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), biotechnologická společnost vyvíjející personalizované imunoterapie DCVax® pro rakoviny solidních...


May 31, 2018, 06:17 ET Spoločnosť NW Bio organizuje počas konferencie ASCO v sekcii pre odborníkov diskusiu o predbežných dátach z klinického skúšania fázy 3

Spoločnosť Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), biotechnologická spoločnosť vyvíjajúca personalizovanú imunitnú terapiu solídnych...


May 31, 2018, 05:48 ET NW Bio presentará datos interinos del ensayo de Fase 3 en la sesión de expertos de la industria durante la Conferencia de la ASCO

Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), una empresa de biotecnología que desarrolla inmunoterapias personalizadas DCVax® para distintos...


May 31, 2018, 04:28 ET Представители NW Bio представят предварительные результаты 3-й фазы клинических испытаний в ходе презентации на ASCO

Компания Northwest Biotherapeutics (код OTCQB: NWBO) (NW Bio) - биотехнологическое предприятие, специализирующееся на разработке персонализированной...


May 31, 2018, 03:57 ET NW Bio omówi dane przejściowe z trzeciej fazy badań w sesji branżowej w trakcie konferencji ASCO

Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), firma biotechnologiczna opracowująca spersonalizowane terapie odpornościowe DCVax® w leczeniu guzów ...


May 30, 2018, 11:31 ET NWBio annonce la publication scientifique de données de survie intermédiaires tirées de l'essai de phase 3 de DCVax®-L pour la tumeur du cerveau glioblastome

Aujourd'hui, Northwest Biotherapeutics (OTCQB : NWBO) -- (« NW Bio »), une société de biotechnologie qui met au point des thérapies immunitaires...


May 30, 2018, 05:48 ET NWBio publica los datos interinos de supervivencia del ensayo de fase 3 con DCVax®-L para el glioblastoma

Northwest Biotherapeutics (OTCQB: NWBO) -- ("NW Bio"), una empresa de biotecnología que desarrolla las terapias inmunológicas personalizadas DCVax®...


May 30, 2018, 03:27 ET NWBio gibt wissenschaftliche Publikation der Interim-Überlebensdaten aus Phase-3-Studie zu DCVax®-L für Glioblastom-Gehirntumore bekannt

Northwest Biotherapeutics (OTCQB: NWBO) -- („NW Bio"), ein Biotechnologieunternehmen, das unter der Bezeichnung DCVax® personalisierte Immuntherapien ...


May 29, 2018, 10:24 ET NWBio Announces Scientific Publication of Interim Survival Data From Phase 3 Trial of DCVax®-L for Glioblastoma Brain Cancer

Northwest Biotherapeutics (OTCQB: NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor...